

Lactoferrin Immunity Benefits in Infant Health

Lactoferrin supporting early life immunity

Dr Neill Haggarty
Research Consultant



Ingredients by



Dairy for life

Introduction

- **Human breastmilk is the gold standard reference for infant formula development. When considering the protein component, breastmilk informs the total content, amino acid profile and composition of minor proteins. Minor proteins such as lactoferrin are often at higher concentrations in human milk than cow's milk.**
- **Lactoferrin is known for its role in natural defence mechanisms, especially its anti-microbial and immune modulating benefits.**
- **Lactoferrin also has antioxidant properties, anti-inflammatory effects, may facilitate iron absorption and may have a prebiotic effect to support healthy gut microflora.**
- **SureStart™ Lactoferrin can be used to increase the content of lactoferrin in infant formula.**



Human breast milk is the ideal source of nutrients to support healthy growth and development of infants. In addition, breast milk contains an abundance of bioactive components that are highly likely to be of physiological significance. In particular, there are unique biochemical and immunological factors that provide protection to the infant against infection.

When breastfeeding isn't possible, human milk substitutes such as infant formula are considered the only safe alternative by the World Health Organisation^{1,2}. However, it is accepted that several outcomes of breastfed infants are superior to those of formula-fed infants, both in the short and long term. Breastmilk composition is the gold standard reference when manufacturing infant formula³.

Human milk contains bioactive proteins, lipids, and carbohydrates that stimulate intestinal development, actively protect the infant from pathogenic infection, and facilitate the establishment of the microbiota⁴⁻⁶. Significantly, early life immunity is characterized by impaired functions of innate (natural) and adaptive (acquired) immune responses. This immune status makes newborns more susceptible to infections and allergic diseases. One of the critical roles of breast milk is to protect the vulnerable newborn against subsequent infection by both directing correct maturation of the innate and adaptive immune systems, and by delivering components with direct anti-microbial activities^{3,7-9}. One of the key components in human milk that may have roles in both immune system maturation and as an anti-microbial agent is lactoferrin.

Human milk and cow's milk are compositionally different including both the total level of protein and the composition of the individual protein components (Table 1).

Table 1.
Protein Content in Human and Cow's Milk¹⁰⁻¹³

Protein	Human Milk (g/L)	Cow's Milk (g/L)	Typical Infant Formula (g/L)
Total protein	9-11	33	15
Casein	3-5	26	6
Whey Protein	4-6	5-7	9
β-lactoglobulin	-	3-4	4.5
α-lactalbumin	3-4	1	1.2
Serum albumin	0.3	0.4	-
Immunoglobulins	0.6-1.2	0.7	-
Lactoferrin	1-3	0.1-0.4	0.01-0.1 ¹

1. Theoretical level in unfortified IF assuming Lf is ~1% of whey protein and upper level of fortified IF

One of the most abundant proteins in human milk is lactoferrin but it is present at only minor levels in bovine milk. The reported typical breastmilk lactoferrin content is about 1-3 g/L (Table 1). The lactoferrin concentration in human milk has been reported to be consistent across different ethnicities and geographies (Figure 1¹⁴). The concentration of lactoferrin declines with time over lactation both in human milk (concentrations ranging from 6 g/L in early milk (<28 days lactation) to 2 g/L in mature milk)¹⁵, and bovine milk (ranging from 0.8 g/L in colostrum to 0.1 g/L in mature milk)¹⁶, as has been seen with other major milk proteins.




Figure 1. The concentration of Lactoferrin in Human Milk¹⁴



LACTOFERRIN



Lactoferrin is a multifunctional iron-binding glycoprotein of the transferrin family^{17,18} that occurs naturally in milk with partial iron saturation (15-20% saturated). Iron binding gives lactoferrin its characteristic pink colour¹. Human and cow's milk lactoferrin have a high degree of similarity^{19,20}, although human lactoferrin has a lower level of iron saturation. Lactoferrin is also present in many other biological fluids such as tears, saliva, and other secretions, and is thought to play an important role in defence against microbial invasion¹⁷.

BIOLOGICAL ROLES OF LACTOFERRIN

There have been many studies and reviews published describing the functions and roles of lactoferrin²¹⁻²⁴. These functions include:

- Anti-bacterial and anti-viral activity
- Anti-inflammatory properties
- Enhancement of gut mucosal immunity and protection
- Anti-oxidant properties
- May help absorption of iron from the diet
- Prebiotic effect

Many studies have shown that lactoferrin functions as a prominent component of the first line of host defence against infection and may be important for the protection of the vulnerable newborn with an immature immune function²⁵. Lactoferrin has a broad range of anti-microbial activities against a range of bacterial, viral and fungal pathogens²⁶⁻²⁸. It is now known that several mechanisms contribute to the broad-spectrum anti-infective and anti-inflammatory roles of lactoferrin^{29,30}. These include the ability of lactoferrin to bind iron making it unavailable to pathogenic microorganisms therefore preventing their growth and proliferation^{31,32}. Several peptides generated during lactoferrin digestion have also been shown to have potent anti-microbial properties^{33,34}. Additionally, lactoferrin possesses indirect activity, often through prevention of pathogen invasion by blocking interaction with receptors used for entry on host cells^{35,36}.

Further research suggests that lactoferrin's ability to provide immune protection may also be due to other immune-modulating and anti-inflammatory properties that may enhance gut mucosal immunity and protection³⁷⁻⁴¹. In vitro and in vivo studies suggest the existence of multiple mechanism that include immune cell recruitment, modulation of chemokine/cytokine production and the regulation of production of reactive oxygen species. These studies also suggest that lactoferrin may affect both innate and adaptive immune responses and modulate both acute and chronic inflammation^{21,37-43}.

Lactoferrin is a mediator that naturally bridges the innate and adaptive immune functions by regulating target cell response, including those involved in oxidative stress and systemic inflammatory responses. It is also recognised as a significant contributor in regulation of antigen presentation and development of productive T helper cell response⁴⁴.

Results from in vitro and in vivo studies show that lactoferrin is capable of interacting with a range innate immune cells responsible for front line immunity, including granulocytes, lymphocytes, macrophages and natural killer (NK) cells, thereby enhancing their functions such as proliferation, maturation, migration, cytokine production and cytotoxicity⁴⁵⁻⁴⁹.

Lactoferrin can also affect cells of the adaptive immune system⁵⁰⁻⁵³. Lactoferrin may promote the differentiation of immature B-cells into efficient antigen-presenting cells (APCs) and may assist the maturation of T-cell precursors into competent T helper cells. Lactoferrin can change the balance of Th1 and Th2 cellular subsets that helps limit excessive inflammatory responses⁵⁴.

Lactoferrin also enhances immunoglobulin secretion in the gut, proliferation of immune cells and increases the production of immune regulating messengers in the gut^{33,55,56}.

Finally, lactoferrin may also mediate iron absorption in the gut. Receptors have been identified in the gut which can bind to lactoferrin facilitating iron absorption into the cells⁵⁷. Some animal model studies have supported the hypothesis that lactoferrin facilitates iron absorption but convincing evidence from infant studies is lacking⁵⁸, although two recent studies do report the ability of lactoferrin to improve iron status in infants^{59,60}.



HUMAN EFFICACY STUDIES OF LACTOFERRIN

Although the outcomes from human studies have been variable⁶¹ the strongest evidence from human studies is for a protective role of lactoferrin against infection.

A recent infant clinical study in healthy infants aged 5+ months given lactoferrin-supplemented infant formula for 3 months reported a significant reduction in respiratory tract infections and symptoms (Figure 2) using a dose of 38mg/100g powder⁶². An earlier randomised trial in infants fed infant formula containing 85mg lactoferrin/100ml (~600mg/100g powder) resulted in fewer respiratory tract infections and improved iron status⁵⁹. A study in older infants (12-18 months) given lactoferrin (0.5g twice a day) showed a decrease in the longitudinal prevalence and severity of diarrhea, but not in incidence⁶³.




Figure 2. Morbidity episodes* in infants fed control or bovine lactoferrin-containing infant formula⁶²

*all effects were statistically significant $p < 0.05$

A very recent study in 4 month old Kenyan infants showed that apo-lactoferrin (non-iron saturated lactoferrin), 1.41g, added to a test meal containing FeSO_4 significantly increased iron absorption (+56%) compared to a meal without apo-lactoferrin⁶⁰.

Lactoferrin has also been shown in studies with preterm infants to promote the growth of beneficial gut bifidobacteria, thus helping to establish a microflora balance that is important for a healthy immune system^{10,64,65}. A more recent study showed that high levels of fecal lactoferrin in neonates, particularly in the first days of life, could represent an important factor in the initiation, development and/or composition of the neonatal gut microbiota⁶⁶.

However other studies have not reported the same prebiotic effect, so further work is needed in this area to determine the role that lactoferrin plays in the development of a healthy gut microflora. Since early host-microbe interaction is a crucial component of healthy immune and metabolic programming, high levels of fecal lactoferrin in neonates may beneficially contribute to the immunologic maturation and well-being of the newborn, especially in pre-term infants.

Further insights on the immune protection benefits of lactoferrin come from studies in vulnerable populations. Analysis of pooled data from two studies on preterm infants (<2500g⁶⁷ and <2000g⁶⁸ birth weight) given 200mg/kg/d of bovine lactoferrin for 4 weeks concluded that lactoferrin had a protective effect against the risk of development of late-onset sepsis, particularly in infants <1000g and among infants with low human milk intake⁶⁹. In another study, lactoferrin supplementation in preterm infants reduced the relative risk of late onset sepsis by up to 80% in non-mothers milk fed infants⁷⁰. Recent systematic reviews and meta-analyses found that lactoferrin supplementation not only reduced the rate of any late onset sepsis in preterm infants, but also reduced the risk of infection and necrotising enterocolitis^{71,72}. However, other studies have shown contradictory results. In the ELFIN study in very preterm infants no effect of lactoferrin on infection, mortality or morbidity was found⁷³. Another study in very preterm infants also found no effect of lactoferrin on mortality and morbidity, although lactoferrin might reduce late-onset sepsis⁷⁴.

There are several reasons why lactoferrin supplementation trials may have inconsistent results. Some possibilities are differences in the population enrolled, the quality and bioactivity of the lactoferrin used, the lactoferrin dose used, the outcome determinations and the presence of other confounding variables not adequately measured.

Overall, the combination of lactoferrin's bioactive properties for immune defence and for gut protection and health support its addition to cow's milk based infant formula to more closely match the levels in human milk.

SAFETY OF COW'S MILK DERIVED LACTOFERRIN INGREDIENTS

Lactoferrin can be extracted and concentrated from cow's milk and used as an ingredient in a number of applications including paediatric nutrition. The lactoferrin is generally 90-95% pure and is then either freeze-dried or spray-dried for dry-blending into infant formula or other powdered nutritional products. Studies have shown that with the right processing conditions, freeze-dried and spray-dried lactoferrin have minimal heat damage and denaturation, and retain excellent solubility⁷⁵.

Several studies using cow's milk derived lactoferrin demonstrate the safety of these ingredients for use in infant formula⁷⁶. Cow's milk derived lactoferrin was accepted by the USFDA as a substance Generally Recommended As Safe (GRAS) in August 2001, and was approved as a novel food for use in infant formula by the European Commission in 2012.

CONSUMER INSIGHTS

Lactoferrin is most commonly found in baby foods in the Asia Pacific region where there has been an increasing number of launches of infant formula and baby foods containing added lactoferrin over the last 10 years⁷⁷. Consumer research in China, 2016,⁷⁸ found that 64% of female users of infant milk formula had heard of lactoferrin and of those 50% associated lactoferrin with enhancing baby's immunity (Figure 3). A similar level of awareness was reported more recently⁷⁹ with 28% of parents associating lactoferrin with immunity and protection. 53% of parents consider "the more the better" when it comes to lactoferrin⁸⁰.




Figure 3. Parents awareness of the benefits of lactoferrin⁷⁸

Base: China: 1,910 female internet users aged 20-39 who are infant formula users who are aware of lactoferrin



Summary

Human milk provides the optimal nutrition for growth, development and immune support, especially needed in the first few months of life. Human milk contains an array of proteins that both supply essential amino acid as well as having bioactive properties. Lactoferrin is one of the most abundant proteins in human milk, and has anti-bacterial and anti-viral properties, making it a useful part of the first line of defence when the immune system is vulnerable. Clinical studies of the bovine Lactoferrin ingredient have shown potential for protection against infection. Therefore, Lactoferrin can be added to infant formula to bring the composition closer to human milk and to provide additional immunity benefits.

REFERENCES

1. National Health and Medical Research Council (2012) Infant feeding guidelines: Summary
2. World Health Organisation (2004) Guideline principles for feeding infants and young children during emergencies. WHO
3. Lönnerdal B (2014) Infant formula and infant nutrition: bioactive proteins of human milk and implications for composition of infant formulas. *Am J Clin Nutr* 99:712S–717S,
4. Donovan S (2006) Role of human milk components in gastrointestinal development: current knowledge and future needs. *J Pediatr* 149: S49–S61
5. Walker WA (2013) Initial intestinal colonization in the human infant and immune homeostasis. *Ann Nutr Metab* 63:8–15
6. Goldman AS (2000) Modulation of the gastrointestinal tract of infants by human milk. Interfaces and interactions. An evolutionary perspective. *J Nutr* 130:426S–431S
7. Andersson Y, Hammarstrom M.L, Lönnerdal B, Graverholt G, Falt H, Hernell O (2009) Formula feeding skews immune cell composition toward adaptive immunity compared to breastfeeding. *J Immunol* 183:4322–4328
8. Bailey M, Haverson K, Inman C, Harris C, Jones P, Corfield G, Miller B, Stokes C (2005) The development of the mucosal immune system pre- and post-weaning: balancing regulatory and effector function. *Proc Nutr Soc* 64:451–457
9. Battersby AJ, Gibbons DL (2013) The gut mucosal immune system in the neonatal period. *Pediatr Allergy Immunol* 24:414–21
10. Wakabayashi H, Yamauchi K, Takase M (2006) Lactoferrin research, technology and applications. *Intl Dairy J* 16:1241–1251
11. Kuwata Y, Yajima T, Kaneko T (1997) Recent and future improvements of protein fraction in cow's milk-based infant formula. In *Milk composition, production and biotechnology* (ed Welch et al), pp. 215–230. CAB International
12. Rudloff S, Kunz C (1997) Protein and non-protein nitrogen components in human milk, bovine milk, and infant formula: Quantitative and qualitative aspects in infant nutrition. *J Ped Gastroenterol Nutr* 24:328–344
13. Swaisgood HE (1995) Nitrogenous components of milk. F. Protein and amino acid composition of bovine milk. In *Handbook of milk composition*, (RG Jensen ed), pp. 464–468. Academic Press, NY
14. Lien E, Jackson J, Kuhlman C, Pramuk K, Lonnerdal B, Janszen D (2004) Variations in concentrations of lactoferrin in human milk: a nine country survey. In *Protecting Infants through Human Milk*, (eds Pickering et al), pp. 423–426. Kluwer Academic/Plenum Publishers
15. Rai D, Adelman AS, Zhuang W, Rai GP, Boettcher J, Lonnerdal B (2014) Longitudinal changes in lactoferrin concentrations in human milk: a global systematic review. *Crit Rev Food Sci Nutr* 54:1539–1547
16. Sanchez L, Aranda P, Perez M.D, Calvo M (1988) Concentration of lactoferrin and transferrin throughout lactation in cow's colostrum and milk. *Biol Chem Hoppe Seyler* 369:1005–1008
17. Lönnerdal B, Iyer S (1995) Lactoferrin: molecular structure and biological function. *Annu Rev Nutr* 15:93–110
18. Steijns JM, van Hooijdonk AC (2000) Occurrence, structure, biochemical properties and technological characteristics of lactoferrin. *Br J Nutr* 84:S11–S17
19. Goodman RE, Schanbacher FL (1991) Bovine lactoferrin mRNA: sequence, analysis and expression in the mammary gland. *Biochem Biophys Res Comm* 180:75–84
20. Pierce A, Colavizza D, Benaissa M, Maes P, Tartar A, Montreuil J & Spik G (1991) Molecular cloning and sequence analysis of bovine lactotransferrin. *Eur J Biochem* 196:177–184
21. Sienkiewicz M, A Jaśkiewicz, A Tarasiuk (2021) Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance. *Critical Reviews in Food Science and Nutrition*, Published online 08 March 2021.
22. Telang S. (2018) Lactoferrin: A critical player in neonatal host defense. *Nutrients*, 10:1228.
23. Legrand D. (2012) Lactoferrin, a key molecule in immune and inflammatory processes. *Biochemistry and Cell Biology*, 90:252–268.
24. Embleton ND, Berrington JE, McGuire W, Stewart CJ, Cummings SP (2013) Lactoferrin: Antimicrobial activity and therapeutic potential. *Sem Fetal Neonat Med* 18:143–149
25. Ward PP, Uribe-Luna, S, Conneely OM (2002) Lactoferrin and host defence. *Biochem Cell Biol* 80:95–102.
26. Berlutti F, Pantanella F, Natalizi T, Frioni A, Paesano R, Polimeni A, Valenti P (2011) Antiviral Properties of Lactoferrin—A Natural Immunity Molecule. *Molecules* 16:6992–7018
27. Leboffe L, Giansanti F, Antonini G (2009) Antifungal and antiparasitic activities of lactoferrin. *Anti-Cancer Agents in Med Chem* 8:114–127
28. Orsi N (2004) The antimicrobial activity of lactoferrin: current status and perspectives. *Biomaterials* 17:189–96
29. Naidu AS, Arnold RR (1997) Influence of lactoferrin on host-microbe interactions, in: *Lactoferrin: Interactions and Biological Functions*, pp259–275, Humana Press, Ottawa New Jersey
30. Baveye S, Ellass E, Mazurier J, Spik G, Legrand D (1999) Lactoferrin: A multifunctional glycoprotein involved in the modulation of the inflammatory process. *Clin Chem Lab Med* 37:281–286
31. Arnold RR, Brewer M, Gauthier JJ (1980) Bactericidal activity of human lactoferrin: sensitivity of a variety of microorganisms. *Infect Immun* 28:893–898
32. Arnold RR, Cole MF, McGhee JR (1977) A bactericidal effect for human lactoferrin. *Science* 197:263–265
33. Tomita M, Wakabayashi H, Yamauchi K, Teraguchi S, Hayasawa H (2002) Bovine lactoferrin and lactoferricin derived from milk: production and applications. *Biochem Cell Biol* 80:109–12
34. Sinha M, Kaushik S, Kaur P, Sharma S, Singh TP (2013) Antimicrobial lactoferrin peptides: the hidden players in the protective function of a multifunctional protein. *Int J Pept* 2013:390230
35. Kawasaki Y, Tazume S, Shimizu K, Matsuzawa H, Dosako S, Isoda H, et al. (2000) Inhibitory effects of bovine lactoferrin on the adherence of enterotoxigenic *Escherichia coli* to host cells. *Biosci Biotechnol Biochem* 64:348–54
36. Drobni P, Naslund J, Evander M (2004) Lactoferrin inhibits human papillomavirus binding and uptake in vitro. *Antiviral Res* 64:63–8
37. Legrand D, Ellass E, Pierce A, Mazurier J (2004) Lactoferrin and host defence: an overview of its immunomodulating and anti-inflammatory properties. *Biomaterials* 17:225–229

38. Legrand D (2012) Lactoferrin, a key molecule in immune and inflammatory processes. *Biochem Cell Biol* 90:252–268
39. Conneely OM (2001) Anti-inflammatory activities of lactoferrin. *J Am Coll Nutr* 20:389S–395S
40. Legrand D (2016) Overview of Lactoferrin as a natural immune modulator. *J Ped* 173:S10–S15
41. Kruzel ML, Bacsı A, Choudhury B, Sur S, Boldogh I (2006) Lactoferrin decreases pollen antigen-induced allergic airway inflammation in a murine model of asthma. *Immunology* 119:159–166
42. García-Montoya IA, Cendón TS, Arévalo-Gallegos S, Rascón-Cruz Q (2012) Lactoferrin a multiple bioactive protein: an overview. *Biochim Biophys Acta* 1820:226–36
43. de la Rosa G, Yang D, Tewary P, Varadhachary A, Oppenheim JJ (2008) Lactoferrin acts as an alarmin to promote the recruitment and activation of APCs and antigen-specific immune responses. *J Immunol* 180:6868–6876
44. Siqueiros-Cendon T, Arevalo-Gallegos S, Iglesias-Figueroa BF, Garcia-Montoya IA, Salazar MJ, Rascon-Cruz Q (2014) Immunomodulatory effects of lactoferrin. *Acta Pharm Sin* 35:557–566
45. Hwang SA, Wilk KM, Bangale YA, Kruzel ML, Actor JK (2007) Lactoferrin modulation of IL-12 and IL-10 response from activated murine leukocytes. *Med Microbiol Immunol* 196:171–80
46. Shau H, Kim A, Golub SH (1992) Modulation of natural killer and lymphokine-activated killer cell cytotoxicity by lactoferrin. *J Leukocyte Biol* 51:343–349
47. Spadaro M, Caorsi C, Ceruti P, Varadhachary A, Forni G, Pericle F, Giovarelli M (2008) Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells. *FASEB J* 22:2747–2757
48. Zaczynska E, Kocięba M, Śliwińska E, Zimecki M (2014) Bovine lactoferrin enhances proliferation of human peripheral blood lymphocytes and induces cytokine production in whole blood cultures. *Adv Clin Exp Med* 23:871–876
49. Wilk KM, Hwang SA, Actor JK (2007) Lactoferrin modulation of antigen-presenting-cell response to BCG infection. *Postepy Hig Med Dosw* 61:277–282
50. Actor JK, Hwang SA, Kruzel ML (2009) Lactoferrin as a natural immune modulator. *Curr Pharm Des* 15:1956–1973
51. Groot F, Geijtenbeek TB, Sanders RW, Baldwin CE, Sanchez-Hernandez M, Floris R, van Kooyk Y, de Jong EC, Berkhout B (2005) Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN--gp120 interaction. *J Virol* 79:3009–3015
52. Dhennin-Duthille I, Masson M, Damiens E, Fillebeen C, Spik G, Mazurier J (2000) Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. *J Cell Biochem* 79:583–593
53. Bi BY, Lefebvre AM, Duś D, Spik G, Mazurier J (1997) Effect of lactoferrin on proliferation and differentiation of the Jurkat human lymphoblastic T cell line. *Arch Immunol Ther Exp (Warsz)* 45:315–320
54. Fischer R, Debbabi H, Dubarry M, Boyaka P, Tome D (2006) Regulation of physiological and pathological Th1 and Th2 responses by lactoferrin. *Biochem Cell Biol* 84:303–311
55. Sfeir RM, Dubarry M, Boyaka PN, Rautureau M, Tome, D (2004) The mode of oral bovine lactoferrin administration influences mucosal and systemic immune responses in mice. *J Nut* 134:403–409
56. Zimecki M, Mazurier J, Spik G, Kapp JA (1996) Lactoferrin inhibits proliferative response and cytokine production of TH1 but not TH2 cell lines. *Arch Immunol Ther Exp (Warsz)* 44:51–56
57. Kawakami H, Lonnerdal B (1991) Isolation and function of a receptor for human lactoferrin in human fetal intestinal brush-border membranes. *Am J Physiol* 261:G841–G846
58. Lönnerdal B (2009) Nutritional roles of lactoferrin. *Curr Opin Clin Nutr Metab Care* 12:293–297
59. King JC Jr, Cummings GE, Guo N, Trivedi L, Readmond BX, Keane V, Feigelman S, de Waard R (2007) A double-blind, placebo-controlled, pilot study of bovine lactoferrin supplementation in bottle-fed infants. *J Pediatr Gastroenterol Nutr* 44:245–251
60. Mikulic N, Uyoga MA, Mwasi E, Stoffel NU, Zeder C, Karanja S, Zimmermann MB (2020) Iron absorption is greater from apo-lactoferrin and is similar between holo-lactoferrin and ferrous sulfate: Stable iron isotope studies in Kenyan infants. *J Nutr* 150:3200–3207
61. Demmelmair H, Prell C, Timby N, Lönnerdal B (2017) Benefits of Lactoferrin, Osteopontin and Milk Fat Globule Membranes for Infants. *Nutrients* 9:817–838
62. Chen K, Chai L, Li H, Zhang Y, Xie HM, Shang J, Tian W, Yang P, Jiang AC (2016) Effect of bovine lactoferrin from iron-fortified formulas on diarrhea and respiratory tract infections of weaned infants in a randomized controlled trial. *Nutrition* 32:222–227
63. Ochoa TJ, Chea-Woo E, Baiocchi N, Pecho I, Campos M, Prada A, Valdiviezo RN, Lluque A, Lai D, Cleary TG (2013) Randomized double-blind controlled trial of bovine lactoferrin for prevention of diarrhea in children. *J Pediatr* 162:349–356
64. Roberts AK, Chierici R, Sawatzki G, Hill MJ, Volpato S, Vigi V (1992) Supplementation of an adapted formula with bovine lactoferrin: 1. Effect on the infant faecal flora. *Acta Paediatr* 81:119–24
65. Kawaguchi S, Hayashi T, Masano H, Okuyama K, Suzuki T, & Kawase K (1989) Effect of lactoferrin-enriched infant formula on low birth weight infants. *Shuusankiigaku* 19:125–130
66. Mastromarino P, Capobianco D, Campagna G, Laforgia N, Drimaco P, Dileone A, Baldassarre ME (2014) Correlation between lactoferrin and beneficial microbiota in breast milk and infant's feces. *Biometals* 27:1077–86
67. Ochoa TJ, Zegarra J, Cam L, Llanos R, Pezo A, Cruz K, Zea-Vera A, Carcamo C, Campos M, Bellomo S (2015) Randomized controlled trial of lactoferrin for prevention of sepsis in Peruvian neonates less than 2500 g. *Ped Infect Dis J* 34:571–576
68. Ochoa TJ, Zegarra J, Bellomo S, Carcamo CP, Cam L, Castañeda A, Villavicencio A et al. (2020) Randomized controlled trial of bovine lactoferrin for prevention of sepsis and neurodevelopmental impairment in infants weighing less than 2000 grams. *J Pediatr* :118–125
69. Ochoa T, Loli S, Mendoza K, Carcamo C, Bellomo S, Cam L, Castaneda A, Campos M, Jacobs J, Cossey V, Zegarra J (2021) Effect of bovine lactoferrin on prevention of late-onset sepsis in infants <1500 g: a pooled analysis of individual patient data from two randomized controlled trials. *Biochem Cell Biol* 99:14–19
70. Manzoni P, Miliello MA, Rizzollo S, et al. (2019) Is Lactoferrin More Effective in Reducing Late-Onset Sepsis in Preterm Neonates Fed Formula Than in Those Receiving Mother's Own Milk? Secondary Analyses of Two Multicenter Randomized Controlled Trials. *Am J Perinatol* 36(S 02):S120–S125
71. He Y, Cao L, Yu J (2018) Prophylactic lactoferrin for preventing late-onset sepsis and necrotizing enterocolitis in preterm infants: A PRISMA-compliant systematic review and meta-analysis. *Medicine (Baltimore)* 97(35):e11976
72. Pammi M, Suresh G (2017) Enteral lactoferrin supplementation for prevention of sepsis and necrotizing enterocolitis in preterm infants. *Cochrane Database Syst Rev.* Jun 28;6:CD007137
73. Griffiths J, Jenkins P, Vargova M, Bowler U, Juszcak E, King A, et al. (2018) Enteral lactoferrin to prevent infection for very preterm infants: the ELFIN RCT. *Health Technol Assess* 22(74):1–60
74. Tarnow-Mordi WO, Abdel-Latif ME, Martin A, Pammi M, Robledo K, Manzoni P, ET AL. (2020) The effect of lactoferrin supplementation on death or major morbidity in very low birthweight infants (LIFT): a multicentre, double-blind, randomised controlled trial. *Lancet Child Adolesc Health* 4:444–454
75. Wang B, Timilsena YP, Blanch E, Adhikari B. (2017). Characteristics of bovine lactoferrin powders produced through spray and freeze during processes. *Int J Biolog Macromolecules* 95:985–94.
76. Ochoa TJ, Pezo A, Cruz K, Chea-Woo E, Cleary TG (2012) Clinical studies of lactoferrin in children. *Biochem Cell Biol* 90:457–67
77. Mintel Global New Product Launches, July 2021.
78. Mintel, Infant Milk Formula – China, April 2018.
79. Fonterra China Consumer Research, 2019.
80. Mintel, Infant Milk Formula – China, March 2019.



CONTACT US

Fonterra Co-operative Group
109 Fanshawe Street
Auckland 1010, New Zealand
+64 9 374 9000

Disclaimer: Fonterra supports the aim and intent of WHO Code for the Marketing of Breast Milk Substitutes. The WHO states that breast milk is the ideal source of nutrition for infants and that breast milk substitutes are safe & nutritious alternatives to breast milk for infants whose mothers cannot or choose not to breastfeed. The content in this document is based on scientific evidence at the time of writing and intended for informative purposes only. The FONTERRA, DAIRY FOR LIFE, NZMP and SURESTART, LACTOB HN001 and BIFIDOB HN019 trade marks all belong to the Fonterra Group of Companies

Talk to the paediatric dairy ingredient experts

We're passionate about sharing our deep dairy expertise to help you grow your business. Talk to us today about your paediatric dairy ingredient needs.

To find out more or to purchase our ingredients
please visit www.nzmp.com/surestart

